Sareum Holdings (SAR)


Latest News

Late-breaker abstract for SRA737 accepted for AACR

RNS Number: 7737H Sareum Holdings PLC 15 March 2018 (AIM: SAR) 15 March 2018 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sareum notes Sierra Oncology announcement that a late-breaking abstract reporting SRA737 preclinical activity in CCNE1-driven and PARP inhibitor-resistant cancers has been accepted for AACR 2018 Annual Meeting S...

Interim Results

RNS Number: 4750H Sareum Holdings PLC 13 March 2018 (AIM:SAR) 13 March 2018 SAREUM HOLDINGS PLC ("Sareum" or "the Company") HALF-YEARLY RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2017 Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, announces its half-yearly results for th...

Sierra Oncology expands SRA737 development program

RNS Number: 1099G Sareum Holdings PLC 27 February 2018 (AIM: SAR) 27 February 2018 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sareum notes that Sierra Oncology has significantly expanded its clinical development programme for SRA737 Ongoing SRA737 clinical studies expanded to target aggregate enrolment of 200 patients across ten canc...

Preclinical synergy of sra737 and PARP inhibitor

RNS Number: 5858F Sareum Holdings PLC 22 February 2018 (AIM: SAR) 22 February 2018 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sareum notes that Sierra Oncology will report preclinical data demonstrating SRA737 Synergy with PARP inhibitors at the AACR 2018 Annual Meeting Sareum Holdings plc (AIM: SAR), the specialist cancer drug di...

All News

15-03-18Late-breaker abstract for SRA737 accepted for AACRRNS
13-03-18Interim ResultsRNS
27-02-18Sierra Oncology expands SRA737 development programRNS
22-02-18Preclinical synergy of sra737 and PARP inhibitorRNS
13-02-18Notice of Interim ResultsRNS
20-12-17Issue of OptionsRNS
19-12-17Sareum announces new patent approvalStockMarketWire
19-12-17Patent Grants in Japan & China for TYK2 InhibitorsRNS
14-12-17Result of AGMRNS
14-12-17Sareum reports 'significant' year of progressStockMarketWire
14-12-17AGM StatementRNS
20-11-17Notice of AGM and Annual Report & AccountsRNS
31-10-17Sareum notes experiment progressStockMarketWire
31-10-17Sierra Reports Preclinical Data for Chk1 InhibitorRNS
19-10-17Sareum reports maiden profit of £400,000StockMarketWire
19-10-17Final ResultsRNS
09-10-17Sierra Oncology host KOL Meeting on 12 Oct in NYRNS
18-09-17Sierra Oncology to host call on Chk1 inhibitorRNS
22-08-17Sareum profit after tax anticipated to beat expectationsStockMarketWire
22-08-17Pre-Close Trading StatementRNS
19-06-17Sareum to Present at the ICCS 2017RNS
05-06-17Sareum updates on Chk1 inhibitor trialsStockMarketWire
05-06-17Chk1 Clinical Trials UpdateRNS
31-05-17Sareum Holdings notes Sierra Oncology patentsStockMarketWire
31-05-17Sierra Oncology Granted US and EU PatentsRNS
25-05-17Sierra Oncology to Present at ASCO Annual MeetingRNS
09-05-17Sareum to Present at BioTrinity 2017RNS
09-03-17Director Deals - Sareum Holdings PLC (SAR)StockMarketWire
09-03-17Director ShareholdingRNS
20-02-17Sareum swings to H1 pretax profitStockMarketWire
20-02-17Half-year ResultsRNS
09-02-17Notice of Interim ResultsRNS
09-01-17Milestone Payment from Chk1 Licence AgreementRNS
22-12-16Result of General MeetingRNS
15-12-16Result of AGMRNS
06-12-16Directors' Remuneration & General MeetingRNS
29-11-16Sareum to Present at AACR-NCI-EORTC ConferenceRNS
21-11-16Notice of AGMRNS
02-11-16Sareum Holdings narrows FY pretax lossStockMarketWire

RSS feeds

  • Editorial news feed for LSE:SAR Editorial
  • Regulatory news feed for LSE:SAR Regulatory